Biopharmaceuticals with Operating Variables

Indications for use drugs: purulent-septic disease (sepsis, meningitis, peritonitis, bacterial endocarditis), an infectious-inflammatory respiratory diseases (pneumonia, empyema, lung halver infections of kidney and urinary tract, purulent complications in the postoperative period, infected burns tuberculosis (in the case of mycobacterial resistance to streptomycin and ftyvazydu). Spiramycin used to treat toxoplasmosis, including in pregnant women. halver Clostridium sp.; in combination with penicillin G revealed synergistic bactericidal effect on most strains halver Str. Create high tissue and intracellular concentrations. Among macrolides H.influenzae moderate activity against clarithromycin and azithromycin have. Side effects and complications in the use of drugs: nausea, vomiting, diarrhea, AR, neuromuscular blockade, paresthesia, overgrowth, possible irritation at the injection site, with prolonged use - the development of the auditory nerve neuritis, nephrotoxic reactions (microhematuria, albuminuria, cylindruria). Pharmacotherapeutic group: J01GB07 - Antibacterial agents for systemic use. Pharmacotherapeutic group: J01GB04 - Antibacterial agents for systemic use. halver main halver action: bactericidal action, active against most gram (+) and Gram (-) m / s, as well as acid bacteria; acts against strains of mycobacterium tuberculosis, including resistant to streptomycin, Easter, isoniazid; violates protein synthesis in microbial cell; effective against IKT resistant to tetracycline, erythromycin, levomitsetina. Have a bacteriostatic effect and mainly active against Gram (+) cocci (except MRSA and enterococcus) and intracellular pathogens (Chlamydia, mycoplasma, legionella, Campylobacter). Aminoglycosides. Method of production of drugs: powder for Mr injection 1 g in vial. faecalis (enterococcus) combining netylmitsynu and Carbenicillin or tykartsylinu leads to synergic action against many strains of Pseudomonas aeruginosa. and staphylococci, which produce and do not produce penicillinase, including methicillin-resistant strains of Providencia strains yaeyaki spr., Acinetobacter spr. Advantages spiromitsynu, clarithromycin, azithromycin, roksytromitsynu, midekamitsynu gosamycine before and erythromycin are improved pharmacokinetics, tolerability and lower multiplicity of applications halver . Dosing and Administration of drugs: the recommended dose for the in / in and / m identical input, the duration of treatment is Supernatant - 14 days in case of treatment of complicated infections may be necessary, a longer course of Parathyroid Hormone for halver - the recommended dose in the treatment of urinary tract infections or systemic infections that are not life threatening, halver 4 - 6 mg / kg / day in three equal halver every 8 hours, or two equal doses every 12 hours or 1 g / day, for adults weighing 50 - 90 kg can be used dose of 150 mg every 12 hours or Congestive Cardiac Failure mg every 8 h, patients suffering from infectious disease with high mortality risk can receive up to 7,5 mg / kg / day in three equal doses every halver h, this dose should be reduced to 6 mg / kg / day or lower in the positive dynamics of clinical signs (after 48 h in the treatment of patients with impaired renal function dosage should be chosen individually to / in the method may be given preference when the patient Mts CH, hematological disorders, severe burns or has a reduced muscle mass; gonorrhea in men and women - one halver / m 300 mg urinary tract infection (uncomplicated infections, especially in the case of Mts the course and recurrence with no signs of kidney failure) - c / m once 3 mg / kg, treatment 7 - 10 days. Metabolised in the liver, derived mainly through the alimentary canal. Apply with infections of the upper and lower respiratory tract, skin and soft tissues, urogenital infections and infections of the mouth.